Neurocrine Biosciences, Inc. $NBIX Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 34.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 75,000 shares of the company’s stock after selling 40,000 shares during the quarter. Impax Asset Management Group plc owned about 0.08% of Neurocrine Biosciences worth $10,528,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NBIX. JPMorgan Chase & Co. grew its holdings in shares of Neurocrine Biosciences by 59.6% during the second quarter. JPMorgan Chase & Co. now owns 4,261,747 shares of the company’s stock worth $535,659,000 after buying an additional 1,590,749 shares in the last quarter. Norges Bank purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at about $122,278,000. Los Angeles Capital Management LLC grew its stake in Neurocrine Biosciences by 19,454.9% during the 2nd quarter. Los Angeles Capital Management LLC now owns 744,650 shares of the company’s stock valued at $93,595,000 after acquiring an additional 740,842 shares in the last quarter. AQR Capital Management LLC raised its holdings in Neurocrine Biosciences by 40.5% in the 2nd quarter. AQR Capital Management LLC now owns 1,510,015 shares of the company’s stock valued at $189,794,000 after acquiring an additional 435,385 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Neurocrine Biosciences in the 2nd quarter worth approximately $42,933,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Mizuho upped their price target on Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. Stifel Nicolaus boosted their price objective on Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Thursday, January 22nd. Zacks Research lowered Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Finally, Wall Street Zen raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday. Fifteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $176.00.

Neurocrine Biosciences Trading Down 0.2%

Shares of NASDAQ:NBIX opened at $137.44 on Thursday. The company has a market capitalization of $13.70 billion, a price-to-earnings ratio of 32.88, a PEG ratio of 0.65 and a beta of 0.31. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $160.18. The business has a 50-day moving average price of $141.39 and a 200 day moving average price of $140.58.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing the consensus estimate of $2.36 by ($0.48). The company had revenue of $805.50 million for the quarter, compared to analysts’ expectations of $804.21 million. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The company’s quarterly revenue was up 28.3% compared to the same quarter last year. During the same period last year, the business earned $1.69 EPS. As a group, equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong sales momentum — Net product sales were $798.3M in Q4 and $2.83B for full-year 2025, +29% and +22% year-over-year, respectively; company gave INGREZZA® full‑year 2026 net product sales guidance of $2.7–$2.8B, supporting revenue durability. Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
• Positive Sentiment: Analyst backing remains solid — Multiple recent buy/overweight ratings and a median analyst target ~ $179 indicate continued bullish consensus that could support the stock over time. Neurocrine Biosciences Inc. (NBIX) Stock Falls on Q4 2025 Earnings
• Neutral Sentiment: Revenue roughly in line with Street — Reported revenue ~$805.5M (~+28% YoY) compared closely to consensus estimates (mid-$800M), so top-line performance was not the primary driver of the move. Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
• Neutral Sentiment: Full disclosure and management color available — Earnings call transcript and slide deck were posted for investors to review guidance detail and pipeline commentary. Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript Slide Deck
• Negative Sentiment: EPS missed consensus — Reported EPS ($1.88) came in below several Street estimates (reports cite $2.25–$2.36 consensus), which is the main near-term catalyst pressuring the stock. Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
• Negative Sentiment: Market and insider signals — Several reports note an immediate post-earnings share drop and sizable insider sales disclosed in recent months, both of which can add short-term selling pressure. Neurocrine Biosciences Inc. (NBIX) Stock Falls on Q4 2025 Earnings
• Negative Sentiment: Cautious tone for 2026 highlighted by some outlets — Coverage describes company guidance as cautious despite strong Ingrezza sales, which may keep near-term sentiment muted until more clarity emerges. Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance

Insider Activity at Neurocrine Biosciences

In other news, Director Leslie V. Norwalk sold 1,190 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $155.09, for a total transaction of $184,557.10. Following the completion of the transaction, the director directly owned 6,239 shares in the company, valued at $967,606.51. This trade represents a 16.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Kyle Gano sold 36,400 shares of Neurocrine Biosciences stock in a transaction on Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at $18,632,008.90. The trade was a 20.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 61,966 shares of company stock worth $8,625,166 over the last quarter. Company insiders own 4.80% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.